Ivabradine reversed nondipping heart rate in rats with l-NAME-induced hypertension

Clinical and Experimental Pharmacology & Physiology
Tomas Baka, Fedor Simko

Abstract

We hypothesized that decreasing elevated night-time heart rate (HR) in hypertension by administering a bradycardic agent (ivabradine) at bedtime could bring cardiovascular benefit. Since rats are nocturnal animals, they exhibit circadian rhythms phase-shifted relative to humans. Sixty-six Wistar rats were divided into non-diseased controls and rats with l-NAME-induced hypertension to compare the haemodynamic effects of daytime-dosed and night-time-dosed ivabradine. l-NAME-induced hypertension inverted the physiological 5.6% night-to-day HR dip to an undesirable HR rise by 11.1%. Ivabradine dosed at daytime (the rat's resting phase) reverted a night-to-day HR rise to HR dip by 14.2%. These results suggest a cardiovascular benefit of ivabradine dosed at the human's resting phase (night-time) for hypertensive patients with nondipping HR.

References

Apr 4, 1998·Journal of Molecular and Cellular Cardiology·O PechánováF Simko
Sep 24, 1998·Journal of Hypertension·P VerdecchiaC Porcellati
Mar 21, 2000·Journal of Molecular and Cellular Cardiology·I BernátováF Simko
Mar 29, 2000·The Journal of Urology·A HuangH Trachtman
Jun 14, 2005·European Journal of Clinical Investigation·F SimkoI Bernatova
Aug 29, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Benedek ErdosNihal Tümer
Sep 22, 2010·Chronobiology International·Ramón C HermidaJosé R Fernández
Aug 11, 2012·Progress in Brain Research·Christopher J MorrisFrank A J L Scheer
Oct 20, 2012·Cardiovascular Research·Manoraj NavaratnarajahCesare M Terracciano
Jun 7, 2016·Journal of Pineal Research·Fedor SimkoRussel J Reiter
Jun 24, 2017·Clinical and Experimental Pharmacology & Physiology·Jules C Hancox
Feb 1, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Fedor SimkoLudovit Paulis
Feb 13, 2018·Autonomic Neuroscience : Basic & Clinical·Tomas Baka, Fedor Simko
Oct 5, 2018·International Journal of Molecular Sciences·Fedor SimkoLudovit Paulis

❮ Previous
Next ❯

Citations

Aug 6, 2020·Frontiers in Medicine·Peter StankoFedor Simko
Mar 2, 2021·Frontiers in Cardiovascular Medicine·Fedor Simko, Tomas Baka
Jan 8, 2022·Medicinal Research Reviews·Kristina RepovaFedor Simko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.